Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
The UK’s National Health Service will prescribe semaglutide (Wegovy) to about 1.2 million adults who have had a heart attack or stroke and have a BMI of 27 or higher. The move follows NICE’s recommendation and a cost‑effective deal with Novo Nordisk, aiming to cut future cardiovascular events by roughly 20 %.
The National University of Singapore announced a wearable sensor that continuously monitors fatigue and stress, achieving 93% peak‑detection accuracy and ISO‑grade signal quality. The device, built on a metahydrogel platform with AI denoising, could give meditation practitioners a reliable physiological...
Researchers at Johns Hopkins University employed patient‑specific digital heart‑twin models to guide ventricular tachycardia ablations in ten patients, achieving arrhythmia‑free outcomes in eight and only brief episodes in two – a success rate well above the typical 60%. The FDA‑approved...
Scientists from the Harbin Institute of Technology have built DNA‑based nanorobots that can locate and bind SARS‑CoV‑2 virus particles in vitro. The machines, only a few dozen nanometers across, use strand‑displacement chemistry to change shape and deliver drugs directly to...
The FDA released draft guidance in October 2025 that reshapes biosimilar development by emphasizing analytical data. The guidance suggests that robust analytical comparability can replace or reduce comparative efficacy studies. It calls for comprehensive analytical packages using orthogonal techniques such as...
The EMBL‑EMBO AI and Biology symposium in March 2026 highlighted a paradigm shift: artificial intelligence is moving from pattern‑matching to uncovering causal mechanisms in life sciences. Researchers showcased interpretable deep‑learning models for RNA splicing, probed AlphaFold2’s confidence, and revealed hidden...
The European Commission has granted approval for Merck’s Keytruda (pembrolizumab) combined with paclitaxel, with or without Avastin, to treat PD‑L1‑positive, platinum‑resistant ovarian, fallopian‑tube or primary peritoneal carcinoma. The indication covers adults who have received one or two prior systemic regimens...
Epia Neuro, a San Francisco startup, unveiled a brain‑computer interface paired with a motorized glove to restore hand function in stroke patients. The disk‑shaped implant sits under the skull, captures neural intent from undamaged brain regions, and translates it via...
Biocytogen and China’s Sihuan Pharmaceutical have signed a strategic partnership to co‑develop novel antibody therapeutics across several disease areas, including obesity. The deal merges Biocytogen’s fully human antibody discovery platform—featuring target‑humanized mouse models, in‑vivo efficacy systems, and an AI‑driven sequence...
David Sinclair's lab just reversed infertility in mice that had been infertile for 6 months. They took 16-month-old mice, the equivalent of a woman well past menopause, and made them produce offspring again. The belief has always been that mammals run out...
At the ACC 2026 meeting, a Bayesian network meta‑analysis of 2,803 overweight and obese adults showed that the fixed‑dose combination CagriSema outperformed its components, cagrilintide and semaglutide 2.4 mg, across all efficacy measures. CagriSema delivered the greatest absolute and percent weight...
AstraZeneca presented interim data from its Phase III EMERALD-3 trial, evaluating a single priming dose of Imjudo (300 mg) plus Imfinzi (1500 mg) followed by quarterly Imfinzi and transarterial chemoembolisation (TACE) with or without lenvatinib in 760 patients with unresectable hepatocellular carcinoma...
Researchers at Case Western Reserve University reported that nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) can help pancreatic cancer cells survive standard chemotherapy, raising safety concerns for patients and the biohacking community that widely uses these supplements.
Researchers identified the orphan nuclear receptor NR0B2 (also known as SHP) as a protective factor in cartilage, with its expression markedly reduced in osteoarthritic tissue. In male mice, global or chondrocyte‑specific deletion of Nr0b2 worsened pain and joint damage after...
The U.S. Food and Drug Administration has granted expedited approval to Eli Lilly's oral GLP‑1 weight‑loss pill, Foundayo, priced between $149 and $349 per month. The decision pits Lilly against Novo Nordisk’s injectable and oral options and could reshape obesity...
Eli Lilly’s Foundayo became the first new molecular entity approved under the FDA’s National Priority Voucher pilot, clearing in a record 50 days. It is the only GLP‑1 weight‑loss pill that can be taken without food or water restrictions, aiming to...
Scientists have cured type 1 diabetes in mice by creating a blended, or chimeric, immune system that tolerates transplanted insulin‑producing cells without lifelong immunosuppression. The protocol combines donor bone‑marrow stem cells, islet cells, low‑dose radiation, antibodies and the drug baricitinib, allowing...
Actinogen Medical has begun treating the first participant in the open‑label extension (OLE) of its Phase IIb/III XanaMIA trial for Alzheimer’s disease. The OLE allows eligible U.S. and Australian subjects to receive Xanamem 10 mg daily for up to 25 months, collecting...
Cogent Biosciences announced that the U.S. FDA has received a New Drug Application for bezuclastinib under the Real-Time Oncology Review program, targeting gastrointestinal stromal tumor patients who have progressed after imatinib. The Phase III PEAK trial, comparing bezuclastinib plus sunitinib to...
Nionyx Bio, led by CEO Magdalena Tyrpien, captured first place in the 2026 BIO‑Europe Spring Startup Spotlight in Lisbon. The company focuses on a proprietary adeno‑associated virus (AAV) capsid platform paired with a Kidney Atlas to deliver gene therapies for...
So… hot off the press: a NEW weight loss PILL just got FDA approved. We’ve had oral (non-injectable) GLP-1s before — but this is one of the first specifically for weight management. When it reaches Malaysia, it could significantly increase demand...
JenaValve has begun commercializing its Trilogy Transcatheter Heart Valve (THV) system in the United States, becoming the first FDA‑approved transcatheter device for symptomatic, severe aortic regurgitation (ssAR). The valve uses radiopaque locators that attach directly to native leaflets, enabling stable...
The U.S. FDA has approved Foundayo (orforglipron), Lilly’s first oral GLP‑1 pill, for obese or overweight adults with weight‑related health issues, to launch via LillyDirect on April 6, 2026. In the ATTAIN‑1 trial the highest dose produced an average 27.3‑lb (12.4%) weight...
Generare Bioscience, a Paris‑based biotech, announced a €20 million (≈$23.3 million) Series A round led by Alven and Daphni. The company is constructing the largest proprietary library of previously unknown small‑molecule structures extracted from microbial genomes. In 2025 it identified over 200 novel...
The Future Biotech Expo 2026 will take place June 2‑3 at the Hilton Houston North in Texas. It is an international red biotechnology exhibition and conference aimed at accelerating breakthroughs in healthcare. Over 3,500 industry pioneers will attend, with exhibitions,...
Intranasal dantrolene nanoparticles inhibit lipopolysaccharide-induced depression and anxiety behavior in mice [Context: Dantrolene is a skeletal muscle relaxant used for malignant hyperthermia and chronic spasticity from spinal cord injuries, MS, or stroke. It inhibitings calcium release in muscle cells. Common side...
The Q2 2026 catalyst slate highlights several high‑profile FDA decisions that could reshape the breast‑cancer and obesity markets. Replimune plans a BLA resubmission for vusolimogene oderparevec with a PDUFA date of April 10, 2026, while Arvinas expects a June 5, 2026 decision on vepdegestrant, which showed...
Researchers have identified a strain of lactic‑acid bacteria common in kimchi that binds up to 87% of nanoplastics in lab tests. In mouse trials, the probiotic doubled the excretion of these particles, suggesting a dietary route to mitigate microplastic accumulation.
A research team announced that FLAV‑27, an experimental compound targeting the epigenome, restored memory function in mice and nematodes with early Alzheimer’s pathology. The finding shifts focus from amyloid‑beta plaques to gene‑regulation mechanisms, a development that resonates with longevity‑focused biohackers.
Researchers at the National University of Singapore, led by Prof. Ho Ghim Wei, introduced a metahydrogel‑based wearable that continuously monitors fatigue and stress. The device boosts peak‑detection accuracy to 93% and identifies fatigue levels with 92% accuracy, far outpacing commercial...
Amazing how far you can push vibecoding if you know what you need and the general theory behind the tool chains needed to get your result. I can now load a transcriptome dataset, find the pfam associated with that transcript,...
1/@BeamTx announced the publication of clinical data from its Phase 1/2 BEACON clinical trial evaluating risto-cel - formerly known as $BEAM-101 for the treatment of sickle cell disease (SCD). The data was presented at #ASH25 🧵👇 & was published in...
The Trump administration is poised to issue an order that would levy a 100% tariff on imports of patented medicines and their active pharmaceutical ingredients. A draft of the order suggests the tariffs could be announced as early as Thursday,...
Interesting data from Epic medical records - suggests that for many patients in the "real world", they are able to keep the weight off after stopping GLP1s... https://t.co/dHfYdG6rEX #EpicResearch
Young plasma transfer enhances antioxidant defense and preserves structural integrity in aged lung tissue https://t.co/v1lR1EyCKv https://t.co/ZYJu1qNsDl
Researchers from Canada, Brazil and the United States reported that fluvoxamine dramatically reduced fatigue in long COVID patients, achieving a 99% probability of benefit in the 399‑person REVIVE‑TOGETHER trial. The low‑cost antidepressant could become a first‑line option for a condition...
Pharma has varying levels of success developing drugs. That's a boon for biotech Here are the biopharma companies ranked by likelihood of first approval (LoA%) from 2006-2022 $AMGN, $NVO, #Eisai top the list $GSK, #Astellas, $ABBV are at the bottom #learnbiotechinvesting #BiotechPrometheus
Clinicians: UCL and Drug Science invite you to contribute to a controlled exploration of MDMA’s psychological effects. Eligible participants will undergo two medically supervised sessions at UCL. This work aims to build a psychoanalytically grounded model of its therapeutic action....
A new chemistry reported in Nature enables modular, iterative construction of C_sp³–C_sp³ bonds while precisely controlling the three‑dimensional arrangement of attached atoms. The approach leverages interchangeable building blocks to assemble 3D small‑molecule scaffolds, a bond type that is pervasive in...
In 2010, China accounted for fewer than 8% of global clinical trials. By 2020, it had surpassed both US & Europe in registered trials. By 2024, China was initiating more than 5,000 clinical trials a year — a more than...
Injectable “satellite livers” could offer an alternative to liver transplantation by Anne Trafton @MIT Learn more: https://t.co/HZg5qoXutb #HealthTech #ArtificialIntelligence #MachineLearning https://t.co/V4W3VUpDbw
Excelsior Sciences, backed by Deerfield, unveiled an automated platform for small‑molecule discovery that leverages modular "smart blocs" and generative AI. The system integrates iterative carbon‑carbon bond formation, robotic synthesis, and in‑vitro assays into a continuous make‑test‑learn loop. By translating chemical...
Fixing Birth Defects With Bioelectrical Reprogramming (Featuring Michael Levin, PhD) Aging and rejuvenation next? https://t.co/CHaRqozCph
A new review of the GLP-1 receptor drugs @NEJM https://t.co/PK03jApZWB surprisingly, the word inflammation only appears once, in this diagram https://t.co/1PeBakBAQb
Eli Lilly’s anti‑obesity pill Foundayo (orforglipron) became the first new molecular entity approved under the FDA Commissioner’s National Priority Voucher (CNPRV) pilot. The FDA granted approval just 50 days after Lilly filed the NDA, well ahead of its 294‑day target deadline. Foundayo’s...
Title and header via the @cwru press release: New research reveals dangers of ‘anti-aging’ supplements in cancer protection Vitamin B3 could be making chemotherapy less effective in pancreatic cancer patients https://t.co/vIfcvuiS6P Discussion + thoughtful debate welcome👇👨⚕️ https://t.co/aHewoWeIle
3 new trial results for genome editing of sickle cell disease and β-thalassemia @NEJM https://t.co/qGGdjgKqP5 (with summary Table below) https://t.co/RdiM3urCKJ https://t.co/W15cPAfMoS https://t.co/F3PHKuktPx https://t.co/t6Z35S8L7h
Researchers at Johns Hopkins created patient‑specific digital heart twins that simulate electrical activity to plan ventricular tachycardia ablations. By converting high‑resolution MRI scans into 3‑D models, physicians could test virtual ablations and identify optimal targets before entering the operating room....
A look at some promising early stage drug developments coming down the pike at #AACR26. A few of these concepts were not on the radar a couple of years ago: https://t.co/w6oD4CEckq https://t.co/kfR1AXG41K
NAD+ controls circadian rhythmicity during cardiac aging https://t.co/NNVx94IIC8 Fig. 2: Cardiac NAD+ decreases with aging, with restoration by supplementation with nicotinamide riboside. https://t.co/z4uSqKrYjR
